Myriad Genetics (NASDAQ:MYGN) has entered into a research agreement with Intermountain Healthcare, a nonprofit healthcare system, to carry out studies on molecular diagnostic tests developed by the company. This agreement will benefit treatment decisions for patients at Intermountain.
While Myriad has been conducting several studies to help in the rapid uptake of its tests, the recent agreement with Intermountain will be another step in this direction. The collaboration will evaluate Myriad’s … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards